Abstracts tagged "DMARDs and rheumatoid arthritis (RA)"

Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 2240 • 2019 ACR/ARP Annual Meeting
Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis
Chanakya Sharma¹, Samuel Whittle ², Pari Delir Haghighi ³, Frada Burstein ³, Roee Sa'adon ⁴ and Helen Keen ¹, ¹Fiona Stanley Hospital, Perth, Australia, ²The Queen Elizabeth Hospital, Adelaide, Australia, ³Monash University, Melbourne, Australia, ⁴Treato, Or Yehuda, Israel
Background/Purpose: Our hypothesis is that patients have a positive opinion regarding the newer, biologic DMARDs and a negative sentiment towards the conventional synthetic agents. We…
Abstract Number: 551 • 2018 ACR/ARHP Annual Meeting
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
Gezmis Kimyon¹, Sedat Kiraz², Ihsan Ertenli², Orhan Kucuksahin³, Ediz Dalkiliç⁴, Cemal Bes⁵, Nilufer Alpay Kanitez⁶, Timucin Kasifoglu⁷, Hakan Emmungil⁸, Belkıs Nihan Coşkun⁴, Burcu Yagız⁴, Suleyman Serdar Koca⁹, Muhammet Cinar¹⁰, Aşkın Ateş¹¹, Servet Akar¹², Duygu Ersozlu Bakirli¹³, Veli Yazisiz¹⁴, Nazife Sule Yasar Bilge⁷, Muge Aydin Tufan¹⁵, Ridvan Mercan¹⁶, Omer Karadag², Ayse Bahar Kelesoglu¹¹, Onay Gercik¹⁷, Burak Oz⁹, Zeynel Abidin Akar⁹, Sedat Yılmaz¹⁸, Sezin Turan⁸, Yavuz Pehlivan⁴, Ender Terzioglu¹⁴, Levent Kilic², Sukran Erten¹⁹, Emre Tekgöz¹⁰, Koray Tascilar²⁰ and Umut Kalyoncu², ¹Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Rheumatology, Liv Hospital, Ankara, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ⁷Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ⁸Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁹Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ¹⁰Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ¹¹Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ¹²Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹³Department of Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey, ¹⁴Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁵Rheumatology, Baskent University Faculty of Medicine, Adana, Turkey, ¹⁶Rheumatology, Namik Kemal University Faculty of Medicine, Tekirdağ, Turkey, ¹⁷Rheumatology, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁸Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ¹⁹Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ²⁰Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey
Background/Purpose: Methotrexate and leflunomide are anchor conventional synthetic DMARDs (csDMARDs) for rheumatoid arthritis (RA) treatment. Although methotrexate is the usual recommended concomitant csDMARD along with…
Abstract Number: 556 • 2018 ACR/ARHP Annual Meeting
Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims
Robin K. Dore¹, Jenya Antonova² and Jerrold Hill³, ¹Univ of California, Los Angeles, CA, ²Gilead Sciences, Foster City, CA, ³Health Economics Outcomes Research, Real World Evidence, IQVIA, Plymouth Meeting, PA
Background/Purpose: The ACR treat-to-target approach for rheumatoid arthritis (RA) recommends regular assessments of disease activity and adjustment of medication regimen until efficacy goals are met.…
Abstract Number: 1887 • 2018 ACR/ARHP Annual Meeting
Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk^1,2, Michael Evans³, Julia Kay², Megan E. B. Clowse⁴, Esi Morgan⁵, Andreas Reimold⁶, Tracy Johansson⁷, Lindsay Lewis⁸ and Jinoos Yazdany⁹, ¹San Francisco VA Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ³University of California - San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ⁵University of Cincinnati, Cincinnati, OH, ⁶Rheumatology, University of TX Southwestern Medical Center, Dallas, TX, ⁷Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ⁸American College of Rheumatology, Atlanta, GA, ⁹University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic DMARDs and tofacitinib account for a large proportion of drug spending in the U.S. Although TNFi drugs have dominated sales, use of…
Abstract Number: 2455 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Judith Maro¹, Talia Menzin², Kenneth Hornbuckle³, Jon T. Giles⁴, Arthur Kavanaugh⁵, Thomas Dörner⁶, David Martin⁷, Jane Huang¹ and Claudia A. Salinas³, ¹Harvard Medical School, Boston, MA, ²Harvard Pilgrim Health Center, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Columbia University, New York, NY, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷Food and Drug Administration, Indianapolis, IN
Background/Purpose: Individuals with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), compared with…
Abstract Number: 542 • 2017 ACR/ARHP Annual Meeting
Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?
Nevsun Inanc¹, Gulsen Ozen², Yasemin Yalçınkaya¹, Ediz Dalkilic³, Suleyman Serdar Koca⁴, Gerçek Can⁵, Ahmet Karatas⁶, Yavuz Pehlivan⁷, Ayten Yazici⁸, Ayse Cefle⁹, Abdurrahman Tufan¹⁰, Servet Akar¹¹, Soner Senel¹², Burak Oz¹³, Nurullah Akkoc¹⁴ and Fatos Onen¹⁵, ¹Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁴Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, ⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁶Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁷Department of Rheumatology, Uludag University, Bursa, Turkey, ⁸Rheumatology, Kocaeli University, Kocaeli, Turkey, ⁹Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ¹⁰Internal Medicine-Rheumatology, Gazi University Medical School, Rheumatology, Ankara, Turkey, ¹¹Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ¹²Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ¹⁴Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: TURKBIO registry is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011. Demographic and clinical data including age, sex,…
Abstract Number: 1058 • 2017 ACR/ARHP Annual Meeting
Variation in DMARD Therapy Following Methotrexate Failure for Newly-Identified Rheumatoid Arthritis in a National Veterans Health Administration Cohort
John McDougall Jr.^1,2, Cynthia Brandt^3,4, Melissa Skanderson³, Joseph Goulet³ and Liana Fraenkel⁵, ¹National Clinican Scholars Program, Yale School of Medicine, New Haven, CT, ²Dep't. of Rheumatology, Yale School of Medicine, New Haven, CT, ³Veterans Affairs Connecticut Healthcare System, West Haven, CT, ⁴Emergency Medicine, Yale School of Medicine, New Haven, CT, ⁵Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT
Background/Purpose: Absent contraindications to conventional DMARD (cDMARD) use, the Veterans Administration (VA) requires a 3-month trial of 2 cDMARDs prior to the use of biologic…
Abstract Number: 2489 • 2017 ACR/ARHP Annual Meeting
Efficacy and Survival of Biologic DMARD Therapies As Monotherapy: Real World Data
Jose A Gómez-Puerta^1,2, Natalia Duque Zapata¹, Luis Alonso Gonzalez^1,3, Carmen Cerón¹, Monica Vásquez¹ and Oscar Jair Felipe Diaz^1,4, ¹Medicarte IPS, Medellín, Colombia, ²Grupo de Reumatología, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ⁴Clinica Las Vegas, Medellín, Colombia
Background/Purpose: According different international registries, around one third of patients under biologic DMARD (bDMARD) with rheumatoid arthritis (RA) are receiving bDMARD as monotherapy (1-4). In…
Abstract Number: 3194 • 2016 ACR/ARHP Annual Meeting
Factors Related to Physicians’ Prescriptions for Rheumatoid Arthritis Drugs Never Filled or Subsequently Discontinued By Patients
Hong J. Kan¹, Kirill Dyagilev¹, Peter Schulam², Suchi Saria¹, Charles Molta³ and Jeffrey Curtis⁴, ¹John Hopkins University, Baltimore, MD, ²Department of Computer Science, Johns Hopkins University, Baltimore, MD, ³Sun Pharmaceutical, Cranbury, NJ, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatologists have many choices of medications to use for patients with rheumatoid arthritis (RA), but patients may not fill a prescription (primary non-adherence or…
Abstract Number: 1626 • 2016 ACR/ARHP Annual Meeting
In Real Life Rheumatoid Arthritis Patients, Leflunomide Has Limited Impact As a Second Line DMARD after Methotrexate
Gundula Weigt, Anne Erler and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose: In patients with rheumatoid arthritis (RA), in whom methotrexate (MTX) is not inducing remission or at least low disease activity, or is not tolerated,…
Abstract Number: 2237 • 2016 ACR/ARHP Annual Meeting
Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
Lawrence Chang¹, Yoko Tanaka², Cynthia J Larmore¹, Leilei Qian¹, Baojin Zhu¹ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, KS
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are approved in the US for the treatment of RA. Previous studies have indicated significant clinical inertia in moving patients…
Abstract Number: 2631 • 2016 ACR/ARHP Annual Meeting
Trends and Factors Associated with Use of Biologic Agents As Monotherapy Among US Patients with Rheumatoid Arthritis
Chieh-I Chen¹, Wenhui Wei², Stuart Blackburn³, Emma Sullivan³ and James Piercy³, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi US, Inc., Bridgewater, NJ, ³Adelphi Real World, Manchester, United Kingdom
Background/Purpose: For patients with rheumatoid arthritis (RA) receiving a biologic disease-modifying antirheumatic drug (bDMARD), the current standard of care is to use the bDMARD concurrently…
Abstract Number: 2649 • 2015 ACR/ARHP Annual Meeting
Test-Retest Reliability of the 5-Item Compliance Questionnaire Rheumatology and Factors Influencing Its Assessment of Adherence in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Mary J. Bell², Charles Goldsmith³, Imy Chiu¹, Anna Gutlin¹ and Sharron Sandhu¹, ¹Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²Rheum Div/Univ of Toronto, University of Toronto, Toronto, ON, Canada, ³Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for optimal monitoring…
Abstract Number: 2399 • 2014 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Gerolamo Bianchi¹, Antonio Carletto², Oscar Massimiliano Epis³, Crescenzio Scioscia⁴, Angelo Semeraro⁵, Laura Bianchino⁶, Laura Bazzichi⁷, Giovanni Lapadula⁸, Luigi Sinigaglia⁹ and Andrea Lo Monaco¹⁰, ¹Div Reumatologia, ASL3 Genovese, Genoa, Italy, ²Dipartimento di Medicina,U.O. Complessa di Reumatologia ,Azienda Ospedaliera Universitaria di Verona, Verona, Italy, ³Rheumatology Unit, Niguarda Ca' Granda Hospital, Milan, Italy, ⁴University of Bari, Bari, Italy, ⁵P.O. “Valle d'Itria, Martina Franca, Italy, ⁶Roche Spa., Monza, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy, ⁸DIM, Rheumatology Unit, Bari, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Medical Sciences-Rheumatology Unit, Azienda ospedaliero-universitaria Sant'Anna, Ferrara, Italy
Background/Purpose Approximately 50% of patients (pts) with chronic diseases are non-adherent to the therapeutic regimen assigned. In pts with rheumatoid arthritis (RA), the non-adherence to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].